Division of Respiratory Therapy, Georgia State University, Atlanta, GA, USA.
Respir Care. 2012 Apr;57(4):613-26. doi: 10.4187/respcare.01756.
Using an electronic literature search for published articles indexed in PubMed between January 1990 and August 2011, the update of this clinical practice guideline is the result of reviewing 84 clinical trials, 54 reviews, 25 in vitro studies, and 7 evidence-based guidelines. The recommendations below are made following the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) criteria: 1: It is recommended that selection of the appropriate aerosol generator and interface be made based on the patient's age, physical and cognitive ability, cost, and the availability of the prescribed drug for use with a specific device. 2: Nebulizers and pressurized metered-dose inhalers (pMDIs) with valved holding chambers are suggested for use with children ≤ 4 years of age and adults who cannot coordinate the use of pMDI or dry-powder inhaler (DPI). 3: It is suggested that administration of aerosols with DPIs be restricted to patients ≥ 4 years of age who can demonstrate sufficient flow for the specific inhaler. 4: For patients who cannot correctly use a mouthpiece, aerosol masks are suggested as the interface of choice. 5: It is suggested that blow-by not be used for aerosol administration. 6: It is suggested that aerosol therapy be administered with a relaxed and nondistressed breathing pattern. 7: Unit dose medications are suggested to reduce the risk of infection. 8: It is suggested that nebulizer/drug combinations should be used as approved by the FDA. 9: It is recommended that healthcare providers know the correct use of aerosol generators; they should teach and periodically re-teach patients about how to use aerosol devices correctly. 10: It is suggested that intermittent positive-pressure breathing should not be used for aerosol therapy. 11: It is recommended that either nebulizer or pMDI can be used for aerosol delivery during noninvasive ventilation.
使用电子文献检索,检索了 1990 年 1 月至 2011 年 8 月期间在 PubMed 上发表的文章,本临床实践指南的更新是基于 84 项临床试验、54 项综述、25 项体外研究和 7 项基于证据的指南进行回顾的结果。以下建议是根据推荐评估、制定和评估(GRADE)标准制定的:
建议根据患者的年龄、身体和认知能力、成本以及特定设备使用的处方药物的可用性,选择合适的气溶胶发生器和接口。
建议使用带阀室的射流雾化器和压力定量吸入器(pMDI)治疗≤4 岁的儿童和不能协调使用 pMDI 或干粉吸入器(DPI)的成人。
建议将 DPI 吸入器用于≥4 岁的患者,这些患者的气流足以满足特定吸入器的要求。
对于不能正确使用吸嘴的患者,建议使用气雾剂面罩作为首选接口。
建议不要使用吹嘴进行气溶胶给药。
建议在放松和无压力的呼吸模式下进行气溶胶治疗。
建议使用单位剂量药物以降低感染风险。
建议使用经 FDA 批准的雾化器/药物组合。
建议医护人员了解气溶胶发生器的正确使用方法;他们应该教授并定期重新教授患者正确使用气溶胶设备的方法。
建议不要在气溶胶治疗期间使用间歇性正压呼吸。
建议在无创通气期间可以使用雾化器或 pMDI 进行气溶胶输送。